This study examined how acebutolol moves through the body after intravenous administration. Researchers measured drug concentrations in blood and urine to determine clearance rates and distribution. They found that blood clearance averaged 6.55 ml/min/kg and remained stable over time. About 40.5% of the drug was excreted unchanged in urine. The drug followed a two-compartment model with distinct fast and slow half-lives. Plasma protein binding was consistent at 74.3%. The model accurately predicted drug concentrations during extended dosing. These findings may help guide clinical use of acebutolol.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Understanding how drugs move through the body is essential for optimizing treatment. Prior studies have outlined general drug clearance mechanisms, but specific data on acebutolol remains limited. Researchers have explored drug metabolism in various populations, yet precise pharmacokinetic profiles for certain compounds are still emerging. The role of renal clearance in drug elimination is well-documented, but its contribution to acebutolol's disposition is unclear. Blood clearance rates vary widely among drugs, but the consistency of acebutolol's clearance has not been fully established. The relationship between plasma protein binding and drug efficacy is a known area of research, yet acebutolol's binding properties have not been thoroughly examined. The use of two-compartment models to describe drug distribution is a standard approach, but their application to acebutolol has been limited. This uncertainty motivates further investigation into acebutolol's pharmacokinetic behavior.
Purpose Of The Study:
The study found that acebutolol has a mean blood clearance of 6.55 ml/min/kg and a two-compartment model best describes its distribution.
A specific chromatographic assay was used to determine drug concentrations in blood samples.
The model accurately described acebutolol's distribution with fast and slow half-lives of 6.08 and 156.8 minutes.
Renal clearance averaged 2.68 ml/min/kg, and 40.5% of the drug was excreted unchanged in urine.
This study aimed to examine how acebutolol is processed in the body after intravenous administration. Researchers wanted to determine the drug's clearance rates and how it distributes in the body. A specific focus was placed on measuring renal and blood clearance values. The study also sought to evaluate the drug's half-lives and volumes of distribution. Understanding plasma protein binding was another key objective. The researchers wanted to assess whether these parameters remained stable over time and across doses. The study aimed to model drug disposition using a two-compartment approach. The findings could help guide dosing strategies for acebutolol in clinical settings.
Main Methods:
The study involved administering intravenous doses of acebutolol to healthy volunteers. Blood samples were collected to measure drug concentrations using a chromatographic assay. Researchers calculated mean blood and renal clearance rates from these data. The study also assessed the fraction of the drug excreted unchanged in urine. A two-compartment model was used to fit the observed data and estimate half-lives. The volume of the central compartment and steady-state distribution were determined from the model. Plasma protein binding was measured to assess drug availability. The results were analyzed to evaluate consistency across doses and over time.
Main Results:
Acebutolol's mean blood clearance was 6.55 ml/min/kg with low variability. Renal clearance averaged 2.68 ml/min/kg. About 40.5% of the drug was excreted unchanged in urine. The drug followed a two-compartment model with fast and slow half-lives of 6.08 and 156.8 minutes. The central compartment volume was 0.223 L/kg. The steady-state volume of distribution was 1.165 L/kg. Plasma protein binding was 74.3% and did not change with drug concentration. The model accurately predicted blood concentrations during extended dosing.
Conclusions:
The study's findings suggest acebutolol has predictable pharmacokinetic behavior. Blood clearance remained stable across doses and over time. Renal excretion accounted for a significant portion of drug elimination. The two-compartment model accurately described drug distribution. Plasma protein binding was consistent within the tested range. The model's predictions matched observed concentrations during extended dosing. These results support the use of the model for dosing predictions. The findings may inform future studies on acebutolol's clinical use.
Failed At:
2026-07-14T07:45:07.402003+00:00
The unbound fraction was 74.3% and remained consistent across drug concentrations.
The model accurately predicted blood concentrations during an 8-hour regimen, suggesting reliable dosing predictions.